Valuation: Natera, Inc.

Market Cap 40.28B 35.25B 32.49B 30.11B 57.16B 3,823B 58.08B 390B 151B 1,887B 151B 148B 6,522B P/E 2026 *
-169x
P/E 2027 * -1,211x
Enterprise Value 39.26B 34.35B 31.66B 29.35B 55.71B 3,726B 56.61B 380B 148B 1,839B 147B 144B 6,356B EV / Sales 2026 *
14x
EV / Sales 2027 * 11.7x
Free-Float
97.02%
Yield 2026 *
-
Yield 2027 * -
1 day-0.89%
1 week+3.62%
Current month+3.62%
1 month+30.63%
3 months+34.41%
6 months+10.56%
Current year+22.78%
1 week 271.64
Extreme 271.64
288.04
1 month 208.79
Extreme 208.794
288.04
Current year 181
Extreme 181
288.04
1 year 131.81
Extreme 131.8106
288.04
3 years 36.9
Extreme 36.9
288.04
5 years 26.1
Extreme 26.1
288.04
10 years 7.35
Extreme 7.35
288.04
Manager TitleAgeSince
Chief Executive Officer 47 2019-01-01
President 46 2023-08-31
Director of Finance/CFO 45 2017-01-31
Director TitleAgeSince
Chairman 53 2015-04-30
Director/Board Member 53 2006-12-31
Director/Board Member 47 2019-01-01
Date Insider Type Main position Quantity % Market Cap.
06-25Free

Director

1,677 0.0012%
06-25Free

Director

1,646 0.0011%
06-25Free

Director

1,669 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-0.89%+3.62%+77.24%+499.85% 40.64B
-0.19%+1.38%+10.08%+36.29% 23.32B
-1.01%+3.96%-19.84%-37.43% 7.39B
-1.58%+9.99%+22.75%+117.40% 5.42B
-0.31%+2.05%+17.99%+43.70% 2.95B
-5.04%-4.71%-23.70%+1,093.80% 2.05B
-4.35%-0.62%+98.36%-8.11% 1.97B
-3.81%-4.30%+27.95%-24.89% 1.75B
+1.10%+1.10%+19.77%-3.95% 1.65B
-4.16%+0.09%-18.93%-69.14% 1.62B
Average -2.03%+1.65%+21.17%+164.75% 8.88B
Weighted average by Cap. -0.99%+3.39%+40.57%+267.14%

Financials

2026 *2027 *
Net sales 2.8B 2.45B 2.26B 2.09B 3.97B 266B 4.03B 27.06B 10.52B 131B 10.5B 10.28B 453B 3.33B 2.91B 2.68B 2.49B 4.72B 316B 4.8B 32.16B 12.51B 156B 12.49B 12.22B 538B
Net income -224M -196M -181M -168M -318M -21.27B -323M -2.17B -843M -10.5B -841M -823M -36.29B -25.21M -22.06M -20.33M -18.85M -35.78M -2.39B -36.36M -244M -94.82M -1.18B -94.66M -92.61M -4.08B
Net Debt -1.02B -896M -826M -765M -1.45B -97.18B -1.48B -9.9B -3.85B -47.96B -3.84B -3.76B -166B -1.31B -1.15B -1.06B -980M -1.86B -124B -1.89B -12.67B -4.93B -61.39B -4.92B -4.81B -212B
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
26-07-07 US$281.27 -0.89% 1,759,186
26-07-06 US$283.80 +1.60% 1,358,559
26-07-02 US$279.32 +1.10% 1,274,247
26-07-01 US$276.27 +1.78% 1,862,134
26-06-30 US$271.45 -0.32% 1,371,653
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
281.27USD
Average target price
266.00USD
Spread / Average Target
-5.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRA Stock